Should a woman with a prior spontaneous preterm birth receive progesterone therapy to prevent recurrence?

Progesterone Therapy for Prevention of Recurrent Preterm Birth

Women with a prior spontaneous preterm birth and a singleton pregnancy should be offered 17-alpha hydroxyprogesterone caproate (17-OHPC) 250 mg intramuscularly weekly, starting at 16-20 weeks until 36 weeks of gestation. 1

Primary Recommendation

The Society for Maternal-Fetal Medicine (SMFM) 2017 guideline explicitly states that all women with a prior spontaneous preterm birth of a singleton pregnancy should be offered 17-OHPC therapy in subsequent singleton pregnancies. 1 This recommendation is based on the landmark Meis et al. trial showing a 34% reduction in recurrent preterm birth at <37 weeks (from 54.9% to 36.3%), along with significant reductions in severe neonatal complications including intraventricular hemorrhage, necrotizing enterocolitis, and need for supplemental oxygen. 1

Dosing Protocol

• 17-OHPC: 250 mg intramuscularly weekly
• Start: 16-20 weeks of gestation
• Continue: Until 36 weeks of gestation 1

Alternative: Vaginal Progesterone

While 17-OHPC is the guideline-recommended first-line therapy, vaginal progesterone may be considered as an alternative when 17-OHPC is unavailable due to cost, access, or insurance coverage issues. 1 However, the evidence for vaginal progesterone in this specific population is considerably weaker and more controversial.

Evidence Nuances for Vaginal Progesterone:

• Small studies showed benefit, but large, high-quality trials did not. The 2022 systematic review found that when restricted to studies at low risk of bias, vaginal progesterone did NOT reduce preterm birth <37 weeks (RR 0.96) or <34 weeks (RR 0.90). 2

• The O'Brien 2007 trial (659 women) found no differences in preterm birth rates with vaginal progesterone versus placebo in women with prior spontaneous preterm birth. 1

• A 2024 retrospective study in a minority population found no reduction in recurrent preterm birth with either 17-OHPC or vaginal progesterone. 3

Critical Caveat: Cervical Length Monitoring

If you choose vaginal progesterone, perform serial transvaginal ultrasound cervical length measurements starting at 16-24 weeks. The benefit of vaginal progesterone is most convincing in women with both a prior preterm birth and a short cervix (≤25 mm). 4, 5

• Cervix ≤25 mm: Strong evidence supports vaginal progesterone 5
• Cervix >25 mm: Evidence shows vaginal progesterone does NOT prevent recurrent preterm birth 5

What NOT to Do

• Do not use progesterone in multiple gestations for preterm birth prevention—it does not work. 4, 5
• Do not rely solely on vaginal progesterone without cervical length assessment if you're using it instead of 17-OHPC
• Do not use oral progesterone as standard therapy—while one meta-analysis showed promise 6, it is not guideline-recommended and requires further validation

Clinical Algorithm

1. Confirm prior spontaneous preterm birth (20-36 6/7 weeks) in a singleton pregnancy
2. Current pregnancy is singleton
3. Offer 17-OHPC 250 mg IM weekly starting at 16-20 weeks until 36 weeks 1
4. If 17-OHPC unavailable: Consider vaginal progesterone with mandatory serial cervical length screening
   • Start at 16 weeks
   • Perform transvaginal ultrasound cervical length every 2 weeks from 16-24 weeks
   • If cervix ≤25 mm: Continue vaginal progesterone (benefit established)
   • If cervix consistently >25 mm: Questionable benefit, discuss with patient

Important Pitfall

The most recent high-quality evidence (2022 meta-analysis) shows no convincing benefit of vaginal progesterone when analysis is restricted to low-risk-of-bias studies. 2 The apparent benefit in earlier meta-analyses was driven by small studies with high risk of bias and significant small-study effects. This is why 17-OHPC remains the guideline-recommended agent despite ongoing controversy about its efficacy following the negative PROLONG trial.